FDA Requests Antidepressant Labeling Add Warning On Suicidality
This article was originally published in The Pink Sheet Daily
Executive Summary
The public health advisory and labeling change request follows an advisory committee recommendation for a stronger warning on the possible risks of the medications. The warning encourages health care providers to monitor patients closely for suicidal behavior although a link between the medications and suicide has not been established.